Compare S&P Global Inc (SPGI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs TG Therapeutics Inc — how do they compare? S&P Global Inc trades at $411 (market cap $120.48B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: S&P Global Inc is far larger — about 15.8× TG Therapeutics Inc's market cap, and S&P Global Inc pays a 0.95% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SPGI | TGTX | |
|---|---|---|
Market Cap | $120.48B | $7.64B |
Sector | Financials | Health |
52-Week High | $534.79 | $59.06 |
52-Week Low | $370.42 | $26.94 |
Enterprise Value | $131.97B | $7.84B |
Dividend Yield | 0.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $410.26, down 0.17% on the day, with a bearish technical signal from moving averages and ADX. The company reported strong Q2 2026 earnings of $4.83 per share, beating estimates, and maintains robust profitability with a 30.54% net income margin. Recent news highlights expansion in AI and data collaborations, including integration with Microsoft 365 Copilot.
The outlook remains positive with 86% analyst buy ratings and a $523.20 consensus price target, implying significant upside. Risks include competitive pressures and reliance on financial market health. Revenue growth and strategic partnerships support long-term value, but investors should monitor execution against high expectations.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
